Jennifer C. Mika
Areas of Focus
Overview
Jen Mika is a seasoned litigator and regulatory counselor who advises health systems, managed care plans, and other institutional clients on innovative legal solutions. Drawing on more than a decade of experience in government practice, Jen offers clients deep knowledge of compliance with federal and local health care law and a winning track record litigating complex issues. Her distinguished career in government focused on protecting vulnerable populations and included senior roles at the United States Attorney’s Office for the District of Columbia, District of Columbia Office of the Attorney General, and District of Columbia Department on Disability Services.
Career & Education
- District of Columbia
- Senior Assistant United States Attorney and Pretrial Mental Health Coordinator, 2021–2024
- Assistant Attorney General and Special Assistant United States Attorney, Office of the Attorney General for the District of Columbia, 2018–2021
- Assistant General Counsel, District of Columbia Department on Disability Services, 2013–2018
- District of Columbia
- Adjunct Associate Professor, Elder Law and Legal Rhetoric, American University Washington College of Law, 2012–Present
- American University Washington College of Law, J.D., cum laude, 2011
- University of North Carolina at Chapel Hill, B.A., with distinction, 2006
International Studies Honor’s Thesis; Willie P. Mangum Medal in Oratory
- District of Columbia
- New York
- Supreme Court of the United States
- Judge Kenia Seoane López, Superior Court for the District of Columbia
- Judge Aida Melendez, Superior Court for the District of Columbia
- Judge Elizabeth Wingo, Superior Court for the District of Columbia
- Judge Russell F. Canan, Superior Court for the District of Columbia
- Women’s Bar Association, District of Columbia
Jennifer's Insights
Client Alert | 5 min read | 01.27.25
After Trump Executive Orders, FDA Removes Diversity Guidance From Website
Days after President Trump issued an executive order (EO) taking aim at diversity, equity, and inclusion (DEI) programs and prohibiting federal recognition of gender identity apart from biological sex, previously issued draft guidance on diversity in clinical trials was removed from the website of the U.S. Food and Drug Administration (FDA). While the removed guidance was in draft form, it is highly unusual for FDA to revoke or alter draft guidance without issuing a statement or further guidance. This move raises questions about the applicability of statutory obligations to submit clinical trial Diversity Action Plans and the agency’s current thinking on best practices for clinical development.
Client Alert | 4 min read | 01.23.25
Tri-Agencies Release Third Mental Health Parity Report to Congress
Client Alert | 8 min read | 12.20.24
Speaking Engagement | 10.24.24
“Selling Involuntary Medication in the District of Columbia: An Overview of Historical and Current Practices to Inform Clinical Approaches and Policy,” American Academy of Psychiatry and the Law Annual Meeting, Vancouver, BC, Canada
Representative Matters
- Successfully investigated and prosecuted two bank employees charged with financially exploiting a 72-year-old military widow with diminished capacity.
- Successfully investigated and prosecuted a pastor charged with financially exploiting multiple elderly women.
- Successfully investigated and prosecuted nursing home employee and home health aid charged with Financial Exploitation of Elderly and Vulnerable Adults
Jennifer's Insights
Client Alert | 5 min read | 01.27.25
After Trump Executive Orders, FDA Removes Diversity Guidance From Website
Days after President Trump issued an executive order (EO) taking aim at diversity, equity, and inclusion (DEI) programs and prohibiting federal recognition of gender identity apart from biological sex, previously issued draft guidance on diversity in clinical trials was removed from the website of the U.S. Food and Drug Administration (FDA). While the removed guidance was in draft form, it is highly unusual for FDA to revoke or alter draft guidance without issuing a statement or further guidance. This move raises questions about the applicability of statutory obligations to submit clinical trial Diversity Action Plans and the agency’s current thinking on best practices for clinical development.
Client Alert | 4 min read | 01.23.25
Tri-Agencies Release Third Mental Health Parity Report to Congress
Client Alert | 8 min read | 12.20.24
Speaking Engagement | 10.24.24
“Selling Involuntary Medication in the District of Columbia: An Overview of Historical and Current Practices to Inform Clinical Approaches and Policy,” American Academy of Psychiatry and the Law Annual Meeting, Vancouver, BC, Canada
Recognition
- United States Attorney’s Award for Creativity and Innovation, 2023
- Office of the Attorney General’s Award for Distinguished Service for a Trial in an Affirmative Case, 2020
- Executive Office of the United States Attorney’s Director’s Award for Superior Performance by a Special Assistant U.S. Attorney, 2020
Jennifer's Insights
Client Alert | 5 min read | 01.27.25
After Trump Executive Orders, FDA Removes Diversity Guidance From Website
Days after President Trump issued an executive order (EO) taking aim at diversity, equity, and inclusion (DEI) programs and prohibiting federal recognition of gender identity apart from biological sex, previously issued draft guidance on diversity in clinical trials was removed from the website of the U.S. Food and Drug Administration (FDA). While the removed guidance was in draft form, it is highly unusual for FDA to revoke or alter draft guidance without issuing a statement or further guidance. This move raises questions about the applicability of statutory obligations to submit clinical trial Diversity Action Plans and the agency’s current thinking on best practices for clinical development.
Client Alert | 4 min read | 01.23.25
Tri-Agencies Release Third Mental Health Parity Report to Congress
Client Alert | 8 min read | 12.20.24
Speaking Engagement | 10.24.24
“Selling Involuntary Medication in the District of Columbia: An Overview of Historical and Current Practices to Inform Clinical Approaches and Policy,” American Academy of Psychiatry and the Law Annual Meeting, Vancouver, BC, Canada
Insights
Speaking Engagement | 10.24.24
Reactions to the Persistent Gender Disparity in Student Note Publication, 2012 MICH. ST. L. REV. 1685
|01.14.13
"The Persistent Gender Disparity in Student Note Publication," 23 Yale Journal of Law & Feminism 385
|03.08.11
"Lessons Learned from Glamis Gold v. United States," 15 J. ARAB ARB. 21
|2010
“Selling Involuntary Medication in the District of Columbia: An Overview of Historical and Current Practices to Inform Clinical Approaches and Policy,” American Academy of Psychiatry and the Law Annual Meeting, Vancouver, BC, Canada
|10.24.24
Practices
Jennifer's Insights
Client Alert | 5 min read | 01.27.25
After Trump Executive Orders, FDA Removes Diversity Guidance From Website
Days after President Trump issued an executive order (EO) taking aim at diversity, equity, and inclusion (DEI) programs and prohibiting federal recognition of gender identity apart from biological sex, previously issued draft guidance on diversity in clinical trials was removed from the website of the U.S. Food and Drug Administration (FDA). While the removed guidance was in draft form, it is highly unusual for FDA to revoke or alter draft guidance without issuing a statement or further guidance. This move raises questions about the applicability of statutory obligations to submit clinical trial Diversity Action Plans and the agency’s current thinking on best practices for clinical development.
Client Alert | 4 min read | 01.23.25
Tri-Agencies Release Third Mental Health Parity Report to Congress
Client Alert | 8 min read | 12.20.24
Speaking Engagement | 10.24.24
“Selling Involuntary Medication in the District of Columbia: An Overview of Historical and Current Practices to Inform Clinical Approaches and Policy,” American Academy of Psychiatry and the Law Annual Meeting, Vancouver, BC, Canada
